Get started

Pennystocks

Bullish Sector - 5G Play, Golden CrossNokia Corporation engages in the network and technology businesses worldwide. The company operates in four segments: Ultra Broadband Networks, Global Services, IP Networks and Applications, and Nokia Technologies. It focuses on mobile radio including macro radio, small cells, and cloud native radio solutions for communications service providers and enterprises; and provides network planning and optimization, network implementation, and systems integration, as well as company-wide managed services. The company also offers fixed networking solutions, such as copper and fiber access products, solutions, and services. In addition, it provides network infrastructure and professional services for mobile networks; and managed services for the fixed, mobile, Internet protocol (IP), and optical domains. Further, the company offers network planning, implementation, operation, and maintenance services. Additionally, it provides IP/optical networking solutions, including IP routing and optical transport systems, software, and services; software solutions, such as customer experience management, network operations and management, communications and collaborations, policy and charging, as well as Cloud, IoT, security, and analytics platforms; and submarine networks and radio frequency systems. The company has a strategic collaboration with Microsoft. Nokia Corporation was founded in 1865 and is headquartered in Espoo, Finland. Nokia continues receiving 5G contracts. On the Daily Chart, the 50-Day MA is ready to Cross up and over the 200-Day MA, Bullish I think NOK has a shot at reversing its downward trend real soon especially if the USA takes an ownership in the company like many White House officials have been talking about possibly doing to stop China. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:NOKLong
by HotCharts
1
Merger Approved - Huge Drug Company & Dirt Cheap Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom. Today, news that the merger with Upjohn was approved hit the news wires. www.bizjournals.com Mylan is in my opinion, one of the cheapest drug stocks in the sector at current levels. The stock currently trades at only 4x projected 2020 and 2021 earnings. The stock should be upwards of $25 to $30 a share with the merger approval. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
Bullish Charts - Above the Cloud, Ready to Spike, Zika VirusBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Daily Chart: Volume: Bullish PMO Turning Up, Bullish MACD Turning Up, Bullish RSI: Bullish Stochastic: Bullish OBV: Bullish Accumulation: Bullish Sector: Bullish Closed above the cloud on Friday - Bullish On 06/10/2020, Company reported Galidesivir stopped the Zika virus replication. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:BCRXLong
by HotCharts
COVID-19 Vaccine, 1st Effective Drug, USA Secures 500,000 DosesHHS secures 500,000 doses of remdesivir. The Trump administration has secured 500,000 doses of remdesivir, the first drug shown to be effective at treating hospitalized coronavirus patients, ensuring these doses will be for U.S. use. This could mean huge profits for GILD. Indicators are starting to turn up, Bullish. Daily Chart is turning Bullish. I think if the stock breaks above the $77.00 range, it's going to spike. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:GILDLong
by HotCharts
4
Bullish Charts - Golden Cross, Possible BuyoutCloudera, Inc. provides a suite of data analytics and management products in the United States, Europe, and Asia. The company operates through two segments, Subscription and Services. It offers Cloudera Enterprise Data Hub that allows companies to execute various analytic functions against a shared set of governed and secures data in public and private clouds, and data centers; Cloudera Data Warehouse, a hybrid cloud solution for self-service analytics; Cloudera Data Science and Engineering enables users to streamline, simplify, and scale big data processing; and Cloudera Operational DB that enables stream processing and real-time analytics on continuously changing data. The company also provides Hortonworks Data Platform, a data management platform that helps organizations to securely store, process, and analyze various data assets; Cloudera DataFlow, a data platform that collects, curates and analyzes data; Cloudera Data Science Workbench that enables self-service data science for the enterprise; and Cloudera Altus, a platform-as-a-service offering In addition, it offers Cloudera SDX, a solution that enables common security, governance, lineage, and metadata management for multiple analytics functions; and Cloudera Workload XM, an analytic workload experience management cloud service. Further, the company provides consulting, professional, and education services. It serves corporate enterprises and public sector organizations primarily through its direct sales force. The company was founded in 2008 and is headquartered in Palo Alto, California. Daily Chart: Volume: Bullish PMO: Bullish MACD: Bullish RSI: Bullish Stochastic: Bullish OBV: Bullish Accumulation: Bullish Sector: Bullish 50-Day MA just crossed the 100-Day MA and the 200-Day MA - Bullish Search through the recent news, there has been a lot of talk about Cloudera being bought for as high as $18.00 a share. IBM was mentioned as a potential buyer of the company. Market got crushed today, Cloudera was up. - Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
CLong
by HotCharts
Bullish Charts - In-Home COVID-19 TestCo-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah. Daily Chart MACD, RSI & STOCHASTIC are turning up, Bullish Volume is also picking up steam. On 06/09/2020, CODX announced the company will be added to the Russell 2000 and 3000 Indexes On 05/28/2020, Analysts set price targets at $30 and $36 On 05/26/2020, CODX said its Logix Smart Covid-19 test kit was used to demonstrate that the SARS-CoV-2 virus can be detected in cancer tissue of coronavirus patients. On 05/18/2020, Price Target Raised to $35.00 The stock looks like it's on the verge of breaking out much higher. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:CODXLong
by HotCharts
Bullish Charts - Gold at 8 Year High, 2nd Largest Mining Co.Barrick Gold Corporation engages in the exploration, mine development, production, and sale of gold and copper properties. It has ownership interests in producing gold mines that are located in Argentina, Canada, Côte d'Ivoire, the Democratic Republic of Congo, Dominican Republic, Mali, Papua New Guinea, Tanzania, and the United States. The company also has ownership interests in producing copper mines located in Chile, Saudi Arabia, and Zambia; and various other projects located throughout the Americas and Africa. Barrick Gold Corporation was founded in 1983 and is headquartered in Toronto, Canada. Daily Chart Indicators: Volume: Bullish PMO: Bullish MACD: Bullish OBV: Bullish Stochastic: Bullish Sector: Bullish Barrick is getting ready to spike up above the cloud. I think if it breaks above $26 to $26.50, it's going to run. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:GOLDLong
by HotCharts
Bullish Charts - Daily Chart / Indicators look BullishI just got done looking at the GOLDBEES.IN & GOLD daily charts, the charts looks amazing. Indicators: Volume: Bullish PMO: Bullish MACD: Bullish RSI: Bullish Stochastic: Bullish Accumulation: Bullish Sector: Bullish We are trending up above the cloud. I think any pullback will be short lived as seen with today's decline, Bulls came in and started buying. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
TVC:GOLDLong
by HotCharts
COVID-19 Play - Closed Over $5.00 - July is Here!On May 15, 2020, Sorrento had this to say about the COVID-19 vaccine they are working on... “We’re actually so impressed with the data,” Ji said. “One of the antibodies is so powerful that at a very low concentration it is able to 100% completely prevent infection or inhibit the infection. In our studies, not even one virus escaped from the antibody.” "Phase 1 trial could start within 1st few days of July" - (It mentions this date in the article) "We anticipate having enough material to start Phase 1 trial in patients in the ICU within two (2) months." - (The article I listed was published in May.) Ji was talking about the COVID-19 vaccine they have been working on with Mount Sinai Health System & the University of Texas Medical Branch which has access to the live virus. Anyone thinking this is not the real deal, you might want to think again. Moderna's stock is sitting at $63.04 (After Hours) - What does Moderna have that Sorrento doesn't have? In the article listed herein, Sorrento said "within 2 months..." We are within those two (2) months now. (End of June or July) Link to article: www.biospace.com Today, SRNE broke out above $5.00 On the daily chart, as of today, the Volume spiked, and the MACD, RSI, Stochastic & Accumulation are all Bullish or trending up Bullish. Is news forthcoming? After watching what the stock price of Moderna did and looking at Sorrento trading at $5.12, to me, the reward far outweighs any risk. Also, I believe Sorrento is waiting for an Emergency Use Label on their COVID-19 test that can give you a positive or negative within 8 minutes. Does Moderna have a test? I don't think so. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
SLong
by HotCharts
3
Will LPCN Break back Above Previous Support Or...or will it become resistance? There's been a lot of momentum building up ever since LPCN fell off. We saw some insider buying this month but no new news. Meanwhile other companies are presenting at virtual conferences and all that. It makes you wonder if LPCN has enough steam to reclaim its old levels or if this is just a speculation-driven move in the short term. "In May Lipocine received RDA clearance for an investigational new drug application for a Phase 2 study of LPCN 1148. This is a prodrug of bioidentical testosterone to treat liver cirrhosis. Furthermore, the company reported results of a preclinical study of its LPCN 1144 which demonstrated encouraging results according to the company. H.C. Wainright took notice of these milestones and increased its price target on LPCN stock to $3 while maintaining a Buy rating." Quote Source & Info: Can You Make Money With Penny Stocks? 3 Up Big In June
NASDAQ:LPCN
by PennyStocks101
Up..Up..& Away! Priority Review for Cancer DrugAt 8:30 AM NEWS This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer. The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much. Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news. At 4:05 PM NEWS Myovant Sciences to Host Webcast and Conference Call at 8:30 AM EST on June 23, (Tomorrow Morning), to discuss results for Phase 3 SPIRIT 1 Study Evaluating Once-Daily Reglugolix Combination Therapy in Women with Endometriosis. This company has a lot of positive things moving forward including... On 6/11/2020, the stock got a boost with a price target of $45.00 a share. Daily Chart looks good with indicators turning up, Bullish Weekly Chart also looks Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
FCC Approved Contactless Temperature Scanner - Options ActivityJune 8, 2020 Remark Holdings (MARK) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Remark offers products that will help in the crisis and the company owns a stake in Sharecare, the medical startup co-founded by celebrity doctor Mehmet Oz and backed by Oprah Winfrey and Sony (NYSE:SNE). Remark’s innovative products include thermal imaging and scanning solutions that are already in use in Nevada. This artificial intelligence-driven tech can “scan high traffic areas to detect individuals with higher than acceptable skin temperature,” the Wall Street Journal reports. LAS VEGAS, May 27, 2020 /PRNewswire/ -- Remark Holdings, Inc. (NASDAQ: MARK), a diversified global technology company with leading artificial intelligence ("AI") solutions and digital media properties, today announced the launch of a new website, RemarkThermal.com. "Interest in our thermal imaging and scanning solutions is robust across many industries and we believe that enthusiasm warrants a dedicated site for information about our novel solutions," stated Kai-Shing Tao, Chairman and Chief Executive Officer of Remark Holdings, Inc. "What differentiates Remark's thermal cameras are its capabilities beyond thermal temperature scanning. Our proprietary AI software enables monitoring various tasks including people counting, PPE enforcement such as mask wearing, social distancing compliance, contactless access to doors and gates, attendance management, touchless employee check in, object counts, behavior detection, intelligent surveillance and theft control." Remark's Thermal Imaging is used to scan high traffic areas to detect individuals with higher than acceptable skin temperature and track the subject for secondary screening. Each of the Thermal Imaging products is customizable and can operate as a standalone or integrated into centralized control systems, specific to the needs of the customer. Real-time video and audible alerts from individual systems can be sent to a centralized system or monitored live. Systems can be mounted on walls, tripods, or ceilings to scan wider areas. For additional information, please refer to: www.RemarkThermal.com. Options are active. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
6